Long-Term Use of Aldosterone-Receptor Antagonists in Uncontrolled Hypertension: A Retrospective Analysis

Table 2

Changes in biochemical parameters at first followup and end of followup after start of treatment with an aldosterone-receptor antagonist for patients with essential hypertension (EH) and primary aldosteronism (PA). (Values were tested with one-way ANOVA for repeated measurements. Indicated 𝑃 values are for differences between baseline and first followup (a), first and last followup (b), and baseline and last followup (c) after Bonferroni adjustment; 𝑛 represents the number of patients with measurements at all three time points).

		𝑛	Baseline	𝑃 value^a	First FU	𝑃 value^b	End of FU	𝑃 value^c
EH	Serum sodium (mmol/L)	66	141.2 ± 2.7	1.000	140.9 ± 3.0	.927	141.3 ± 3.2	1.000
	Serum potassium (mmol/L)	80	4.0 ± 0.6	<.001	4.4 ± 0.6	1.000	4.4 ± 0.5	<.001
	Serum creatinine (μmol/L)	78	84.6 ± 20.8	<.001	90.8 ± 24.7	.355	93.6 ± 26.2	<.001
PA	Serum sodium (mmol/L)	17	142.9 ± 2.1	.015	141.0 ± 3.4	.103	142.7 ± 3.4	1.000
	Serum potassium (mmol/L)	19	3.4 ± 0.5	<.001	4.3 ± 0.5	1.000	4.3 ± 0.5	<.001
	Serum creatinine (μmol/L)	18	85.7 ± 14.1	.011	96.1 ± 22.6	1.000	95.7 ± 19.6	.169